整合酶抑制剂用于美国围产期感染HIV的经治青年:免疫学、病毒学与人体测量学结局
该研究纳入美国围产期感染HIV的经治青少年和青年556人,分析换用比克替拉韦、多替拉韦、艾维雷韦或拉替拉韦后2年内的病毒学、免疫学及体重结局。换药后1年和2年病毒抑制率各药不一,所有INSTI组CD4均值维持500 cells/mm3以上;女性换用DTG、EVG及男性换用DTG后第一年体重增幅较明显,部分基线非超重者2年内转为超重/肥胖。
要点
- 换用INSTI后2年病毒抑制率BIC 69%、DTG 60%、EVG 68%、RAL 52%。
- 所有INSTI组换药后2年内平均CD4计数均高于500 cells/mm3。
- 女性换用EVG第一年体重平均增加3.8 kg,男性换用DTG增加4.8 kg。
核心结论
- 经治围产期感染HIV青年换用INSTI方案后病毒抑制效果中等,各药存在差异。
- 换用INSTI后平均体重持续增加,提示需关注长期心血管代谢后果。
研究设计与样本
- 基于美国儿科HIV/AIDS队列研究(PHACS)的观察性分析,纳入556名换用BIC、DTG、EVG或RAL的围产期感染HIV经治青少年和青年。
- 采用混合效应模型描述换药后2年内病毒载量、CD4计数、体重和体质指数的变化。
主要发现
- 换药后1年和2年病毒抑制(<200 copies/mL)率分别为BIC 74%和69%、DTG 62%和60%、EVG 76%和68%、RAL 58%和52%。
- 换药后2年内所有INSTI组平均CD4计数均高于500 cells/mm3。
- 换用BIC、DTG、EVG、RAL后第一年平均体重增加:女性分别为0.2、2.5、3.8、-0.2 kg,男性分别为2.3、4.8、2.9、2.6 kg。
- 基线体重不足/健康者换药后2年超重/肥胖比例:女性换用BIC 13%、DTG 18%、EVG 36%、RAL 12%;男性分别为6%、8%、12%、11%。
临床怎么用
- 对经治围产期感染HIV青年选择INSTI时,应综合评估病毒抑制效果及体重增加风险。
- 换用INSTI后需定期监测病毒载量、CD4计数及体重变化,尤其关注女性换用EVG和男性换用DTG的体重增幅。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of integrase strand transfer inhibitors (INSTIs) among adults with HIV is well-established, though adverse effects, particularly weight gain, are common. Comparable data for treatment-experienced adolescents and young adults with perinatally-acquired HIV (AYAPHIV) are limited. METHODS: AYAPHIV in the US-based Pediatric HIV/AIDS Cohort Study who switched to bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) from any prior regimen were eligible. Using mixed-effects models, viral load, CD4 count, weight, and body mass index were described through 2 years after switch for each INSTI. RESULTS: Among 556 AYAPHIV, there were 167 switches to BIC, 282 to DTG, 189 to EVG, and 151 to RAL. Viral suppression (<200 copies/mL) at 1 and 2 years after switch was 74% and 69% for BIC, 62% and 60% for DTG, 76% and 68% for EVG, and 58% and 52% for RAL. Mean CD4 counts were above 500 cells/mm3 after switch through 2 years for all INSTIs. Average weight gain in the first year after switch to BIC, DTG, EVG, and RAL was 0.2, 2.5, 3.8, and -0.2 kilograms for females and 2.3, 4.8, 2.9, and 2.6 kilograms for males. Among previously underweight/healthy individuals, 13%, 18%, 36%, and 12% of females and 6%, 8%, 12%, and 11% of males switching to BIC, DTG, EVG, and RAL were overweight/obese by 2 years after switch. CONCLUSIONS: Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae.
引用
- Patel K, Jaramillo-Underwood A, Karalius B, et al. Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes. Clin Infect Dis. 2026. PMID: 41123331. doi:10.1093/cid/ciaf538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。